Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment

Eunjin JWA; Kyung-Hwan SHIN; Ja-Young KIM; Young-Hee PARK; So-Youn JUNG; Eun-Sook LEE; In-Hae PARK; Keun-Seok LEE; Jungsil RO; Yeon-Joo KIM; Tae-Hyun KIM.
Cancer Research and Treatment ; : 1363-1372, 2016.
Artículo en Inglés | WPRIM | ID: wpr-109741

Documentos relacionados

  1. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
  2. Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
  3. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.
  4. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
  5. Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer.
  6. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
  7. La importancia de la determinación del HER2 en el cáncer gástrico avanzado: a propósito de un caso clínico
  8. Tissue Biology: In Search of a New Paradigm.
  9. [Recurrent Breast Cancer with Pulmonary Lymphangitis Carcinomatosis Case Responding to Trastuzumab Deruxtecan].
  10. A celebration of Fred Brauer's legacy in mathematical biology.